Persisting cost inflation and pricing pressures impact pharma industry: ICRA
The outlook for the Indian pharma industry remains stable, led by expectations of continued steady revenue growth and comfortable margins
ICRA’s sample set of 16 Indian pharma companies — Wockhardt Pharma, Torrent Pharma, Pfizer, Abbott, Cipla, Indoco Remedies, Natco Pharma, Unitech Laboratories, Zydus Lifesciences, Lupin, sun Pharma, Dr Reddy’s, Glenmark Pharma, Aurobindo Pharma, Jubilant Pharmanova and Biocon — registered revenue growth of 4.9 per cent YoY in Q1 FY2023. This was supported by 4.2 per cent growth in the US market and 10.2 per cent in the emerging markets, even as revenues from the domestic and European markets contracted, given the high base of the previous year. The revenue growth rate in Q2 FY2023 is estimated to be largely in line with that of the previous quarter. The rating agency has maintained its growth estimates for its sample set at six to seven per cent to approximately Rs 2 lakh crore in FY2023, marginally lower than the growth of approximatey 7.7 per cent in FY2022. The sample set revenue growth will be supported by six-to-eight per cent YoY growth in the domestic market, four-to-six per cent in the European business, and 11-13 per cent in the emerging markets, even as growth in the US business is expected to be muted at one-to-three per cent.
The Operating Profit Margin (OPM) for the sample set stood at 19.9 per cent in Q1 FY2023, against 23.5 per cent in Q1 FY2022 and 18.3 per cent in Q4 FY2022. The OPM improved on a QoQ basis, supported by favourable currency movement (USD-INR) and the easing of raw material prices to a certain extent. However, the OPM is expected to contract by 120-150 bps in FY2023 as the industry continues to grapple with cost inflation and pricing pressures.
In Q1 FY2023, revenue from the European business for the ICRA sample set witnessed a YoY contraction of 1.2 per cent due to pricing pressures, base effect and higher channel inventory, in addition to unfavourable foreign exchange movement.
Commenting on the headwinds in the European market, Deepak Jotwani, Assistant Vice President and Sector Head, ICRA, said, “While no material demand contraction has been witnessed thus far, the industry remains cautious, given the inflationary pressures and an uncertain macro-economic environment in the European market. The ongoing inflationary pressures in Europe are expected to impact the cost of imports of Key Starting Materials (KSMs)/Active Pharmaceutical Ingredients (APIs), including excipients, especially for acute therapies. Further, the rising energy cost is likely to have an adverse impact on Indian pharma companies with manufacturing operations in Europe. Going forward, market conditions in Europe are expected to remain challenging even as the same are expected to be mitigated selectively to a certain extent by expansion in product offerings, market share gains in the existing products, and entry into new geographies in Europe.”
As for the US market, the sample set reported a 4.2 per cent YoY growth in revenues in Q1 FY2023 against 1.2 per cent YoY growth in Q4 FY2022. The revenue growth was supported by the depreciation of the rupee against the US dollar and new product introductions. ICRA expects mid-to-high single-digit price erosion to continue to exert pressure over the near term, resulting in muted revenue growth for the Indian pharma companies from the US generics market in FY2023.
For the domestic market, ICRA’s sample set witnessed a YoY decline of 4.2 per cent in revenues in Q1 FY2023 on a YoY basis, against 2.8 per cent YoY growth for the IPM. The divergent trend stems from the large base of Q1 FY2022, wherein ICRA’s sample set witnessed a YoY growth of 46.9 per cent, while the YoY growth for IPM stood at 37.8 per cent during the same period. The WPI-linked price hike for NLEM products sustained healthy volumes across both chronic and acute segments. New product introductions and annual price hikes for non-NLEM products are expected to support the revenue growth for ICRA’s sample set in FY2023.
Commenting on the recent pick-up in inspections by the US Food and Drug Administration (FDA), Mythri Macherla, Assistant Vice President and Sector Head, ICRA, said, “With the USFDA re-commencing physical inspections of manufacturing fa